Effectiveness and safety of adding finerenone to treatment with SGLT-2 inhibitors in people with diabetic kidney disease

Addition of finerenone to treatment significantly reduced protein-to-creatinine ratio from 0.52 to 0.41 g/g (p = 0.046).

• The study included 23 patients with diabetic kidney disease treated with sodium-glucose cotransporter 2 (SGLT-2) inhibitors.
• A significant reduction in protein-to-creatinine ratio (UPCR) was observed, with a median decrease of 35%.
• Urinary albumin-to-creatinine ratio (UACR) showed a decreasing trend, with a median decrease of 36%, though not statistically significant (p = 0.15).
• Kidney function remained stable, with a small non-significant decline in estimated glomerular filtration rate (eGFR).
• Serum potassium levels increased slightly, with one case of mild hyperkalemia reported and no treatment discontinuations.

Simplified